About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Miscellaneous

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals announced an annual dividend on Friday, April 7th. Shareholders of record on Wednesday, May 17th will be paid a dividend of $10.60 per share on Friday, May 26th. The ex-dividend date of this dividend is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by $0.70. The biopharmaceutical company earned $33.70 million during the quarter, compared to the consensus estimate of $33.35 million. The business's revenue for the quarter was up 58.3% on a year-over-year basis. During the same period in the previous year, the business earned ($3.30) earnings per share. View Merrimack Pharmaceuticals' Earnings History.

When will Merrimack Pharmaceuticals make its next earnings announcement?

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2018?

2 equities research analysts have issued 1 year price objectives for Merrimack Pharmaceuticals' stock. Their predictions range from $15.00 to $15.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Franklin Resources Inc., Deutsche Bank AG, Teachers Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Merrimack Pharmaceuticals company stock in the last year include Daryl C Drummond and Ulrik B Nielsen. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $10.97.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $146.26 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $-151,740,000.00 in net income (profit) each year or ($7.29) on an earnings per share basis. Merrimack Pharmaceuticals employs 294 workers across the globe.

MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)

MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Merrimack Pharmaceuticals (NASDAQ:MACK) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.